Navigation Links
Verenium 1:12 Reverse Stock Split Takes Effect
Date:9/9/2009

CAMBRIDGE, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, announced that the 1-for-12 reverse split of the Company's common stock became effective at 5:00 p.m. today. Verenium's shares will continue to trade on the NASDAQ Global Market under the symbol "VRNM", with the letter "D" added to the end of the trading symbol for a period of 20 trading days to indicate the reverse stock split has occurred. The Company's symbol will revert back to its original symbol "VRNM" on October 7, 2009. Verenium's common stock has been assigned the new CUSIP number 92340P 209.

Additional information about the reverse stock split is available in Verenium's definitive proxy statement filed with the Securities and Exchange Commission on August 4, 2009 and the Form 8-K filed on September 8, 2009.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through a joint venture with BP, the Company is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities
'/>"/>

SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces,results for the three months to March 31, 2010 . ... ... $718 million ... Total revenues ...
... , April 29, 2010 According to ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), The global oncology,biomarker market is ... 2009 to $9.5,billion in 2014 at a ... Oncology,Biomarkers Market report analyzes the oncology biomarkers diagnostics and,discovery ...
... also known as hypertension, is a serious health risk factor ... the molecular basis of the disease remains poorly understood. ... ( www.genome.org ), scientists have sequenced the genome of ... variants that will help researchers to understand causes of the ...
Cached Biology Technology:Shire's Replenished Portfolio Drives Excellent Quarterly Performance 2Shire's Replenished Portfolio Drives Excellent Quarterly Performance 3Shire's Replenished Portfolio Drives Excellent Quarterly Performance 4Shire's Replenished Portfolio Drives Excellent Quarterly Performance 5Shire's Replenished Portfolio Drives Excellent Quarterly Performance 6Shire's Replenished Portfolio Drives Excellent Quarterly Performance 7Shire's Replenished Portfolio Drives Excellent Quarterly Performance 8Shire's Replenished Portfolio Drives Excellent Quarterly Performance 9Shire's Replenished Portfolio Drives Excellent Quarterly Performance 10Shire's Replenished Portfolio Drives Excellent Quarterly Performance 11Shire's Replenished Portfolio Drives Excellent Quarterly Performance 12Shire's Replenished Portfolio Drives Excellent Quarterly Performance 13Shire's Replenished Portfolio Drives Excellent Quarterly Performance 14Shire's Replenished Portfolio Drives Excellent Quarterly Performance 15Shire's Replenished Portfolio Drives Excellent Quarterly Performance 16Shire's Replenished Portfolio Drives Excellent Quarterly Performance 17Shire's Replenished Portfolio Drives Excellent Quarterly Performance 18Shire's Replenished Portfolio Drives Excellent Quarterly Performance 19Shire's Replenished Portfolio Drives Excellent Quarterly Performance 20Shire's Replenished Portfolio Drives Excellent Quarterly Performance 21Shire's Replenished Portfolio Drives Excellent Quarterly Performance 22Shire's Replenished Portfolio Drives Excellent Quarterly Performance 23Shire's Replenished Portfolio Drives Excellent Quarterly Performance 24Shire's Replenished Portfolio Drives Excellent Quarterly Performance 25Shire's Replenished Portfolio Drives Excellent Quarterly Performance 26Shire's Replenished Portfolio Drives Excellent Quarterly Performance 27Shire's Replenished Portfolio Drives Excellent Quarterly Performance 28Shire's Replenished Portfolio Drives Excellent Quarterly Performance 29Shire's Replenished Portfolio Drives Excellent Quarterly Performance 30Shire's Replenished Portfolio Drives Excellent Quarterly Performance 31Shire's Replenished Portfolio Drives Excellent Quarterly Performance 32Shire's Replenished Portfolio Drives Excellent Quarterly Performance 33MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 2MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 3MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 4
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Researchers from LSU Health Sciences Center New Orleans ... of Child Health and Human Development (NICHD), Harvard School ... Medical School, have found for the first time that ... a week prior to pregnancy appears to significantly elevate ...
... - The inaugural Global Conference on Systems & ... Washington, DC, focuses on the convergence of complex large-scale ... The goal of the conference ... targeted complex systems, examined by domain, each successive year. ...
... early bird registration rates and register online now for ... WHAT: IOF WCO-ECCEO10 is a joint ... European Society for Clinical and Economic Aspects of Osteoporosis ... the world are expected to attend. The exciting scientific ...
Cached Biology News:Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: